Delphine Rea

22PUBLICATIONS
77CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jan 19, 2026
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti

|May 07, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.

Michael J Mauro, Yosuke Minami, Andreas Hochhaus

|Apr 21, 2024
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.

Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis

|Mar 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.

Francois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq

|Feb 23, 2024
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions.

Delphine Rea, Sofiane Fodil, Etienne Lengline

|Jan 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.

Elias Jabbour, Jane Apperley, Jorge Cortes

Pageof 4

Frequent Collaborators

5 joint publications

Michael Mauro

5 joint publications

Andreas Hochhaus

5 joint publications

Gabriel Etienne

4 joint publications

Stéphanie Dulucq